Quality Investor
About 

The Cooper Companies, Inc.

Rank #335Hypergrowth

COO · Nasdaq · Healthcare

The Cooper Companies, Inc. (COO) — Rank #335 by gross profitability (GP/assets 0.21) · ROE 4.5% · Piotroski F-Score 5 / 9.

As-of 2026-09-15 · CIK 0000711404 · all metrics point-in-time as of the filing date.

About

The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers.

Show more

The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment offers spherical, toric, and multifocal contact lenses that address vision challenges, such as astigmatism, presbyopia, and myopia. Its CooperSurgical segment focuses on family and women's health care, which provides fertility products and services, medical devices, and contraception, as well as cryostorage, such as cord blood and cord tissue storage. This segment offers Paragard, a hormone-free intrauterine device; and fertility consumables and equipment, donor gamete services, and genomic services, including genetic testing. The company sells its products to distributors, group purchasing organizations, eye care and health care professionals, including independent practices, corporate retailers, hospitals and clinics, and authorized resellers. The Cooper Companies, Inc.

was founded in 1958 and is headquartered in San Ramon, California.

Industry
Medical Instruments & Supplies
Sector
Healthcare
State
DE
Filer Category
Large accelerated filer
Fiscal Year End
October 31

Price History

COO-52.7% · -13.9% CAGRSPY+80.5% · +12.5% CAGR

Company Snapshot

P/S is the primary valuation lens — earnings are reinvested, not available for P/E.

Market Cap

$10.17B

P/E (annual)

28.6

P/S (annual)

2.5

P/B

1.2

P/OCF (annual)

12.8

Shareholder Yield

-303.2%

Employees

15,000

Industry

Medical Instruments & Supplies

Exchange

Nasdaq

Signal Flags

2 green2 yellow2 red
Revenue growth acceleratingGrowth rate increasing year over year
Sequential beat (rev + EPS)Both revenue and EPS exceeded prior quarter — 1-quarter streak
Dilution above 2%Annual share count increase exceeds 2%. May be acceptable for high-growth companies funding talent via stock compensation
Disclosure regressionA previously-disclosed line item is no longer reported — worth checking the filing for why
Operating margin decliningOperating margin lower than prior year
Balance sheet deterioratingNet cash collapsed with receivables or inventory outpacing revenue

Quality Profile

Profitability

1/1 pass
GP / assets
0.21
Return on equity
4.5%
Gross margin trend
PASS

Safety

1/1 pass
Balance-sheet safety
PASS
Debt / equity
0.52
Current ratio
1.22×
Net cash
-$2.39B

Cash Flow

3/3 pass
Positive FCF
PASS
Cash-backed earnings
PASS
Accruals healthy
PASS
SBC / revenue
1.7%

Growth

1/2 pass
Revenue growth
91.3%
Piotroski F-Score
5 / 9
Share dilution
303.2%

Terry Smith quality gate

Passes 2/5 Terry Smith thresholds

1 of 5 threshold not computable from filed data.

What Growth Is Priced In

Implied revenue growth (10Y)

10.6%

incredible deal

The annual FCF growth rate today's price requires over a 10-year horizon (discount rate 10%, terminal growth 2.5%).

Dilution drag: 303.2% — per-share value needs a total required return of 313.8% once share-count change is priced in.

vs. own 6-year median revenue growth: 18.4%

within its own history

Cost-of-equity sensitivity (implied growth at different discount rates)

r = 8%

6.1%

r = 10% (base)

10.6%

r = 12%

14.4%

Net debt / market cap: 22.3%

Base FCF: $433.7M3Y mean FCF: $475.3M

Valuation History

Current multiple vs historical range at each filing date. Band spans 25th-75th percentile.

P / E

Price / diluted EPS

10.0xFair
1.7xmed 10.1x21.0x

P / S

Price / revenue per share

1.2xFair
0.6xmed 1.4x1.7x

P / B

Price / book value per share

0.5xCheap
0.5xmed 0.9x1.1x

P / GP

Price / gross profit per share

1.8xCheap
1.1xmed 2.2x2.7x

P / FCF

Price / free cash flow per share

8.5xFair
6.2xmed 8.5x23.9x

Revenue growth and the path to profitability (margin trend) are the primary reads at this stage.

Profitability

Gross profitability (GP / assets)

0.21

Primary signal (Novy-Marx).

17th pctl of 37 SIC 38 peers

Return on equity

4.5%

Gross margin

65.5%

72nd pctl of 37 SIC 38 peers

Revenue growth (YoY)

91.3%

Gross margin improving

Margin trend vs prior year.

PASS

Operating Leverage

2018202020212022
Revenue vs COGS
Revenue vs OpEx
Op. Income vs Revenue

Growth

Revenue CAGR (3Y)

7.3%

Revenue CAGR (5Y)

11.0%

Earnings CAGR (3Y)

-1.0%

FCF CAGR (3Y)

-1.3%

Anti-fragile safety

Balance-sheet safety

Composite anti-fragile check.

PASS

Debt / equity

0.52

71st pctl of 35 SIC 38 peers (best = lowest)

Current ratio

1.22×

3rd pctl of 36 SIC 38 peers

Quick ratio

0.51×

Net cash

-$2.39B

Cash & equivalents minus total debt.

Cash-flow health

Free cash flow

$433.70M

Operating cash flow minus capex.

Positive free cash flow

PASS

FCF / net income

0.16

Cash-backing of earnings.

FCF/NI divergence

Unfavorable divergence (yellow flag).

PASS

Accruals healthy

Cash-backed earnings.

PASS

SBC / revenue

1.7%

Stock-based comp intensity.

Piotroski F-Score

F-Score

5 / 9

Fundamental-strength score (0-9).

Lifecycle Phase History

20162022
Capital Return
Hypergrowth
View full financial statements →